In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...
Read More
In a nutshell The authors compared the safety and effectiveness of lisocabtagene maraleucel (liso-cel; Breyanzi) and axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed or refractory (r/r) large B cell lymphoma (LBCL). The study found that both treatments were similarly effective but liso-cel was better tolerated in these...
Read More
In a nutshell This study aimed to review the safety and effectiveness of three chimeric antigen receptor (CAR) T cell therapies, axicabtagene ciloleucel (AXI; Yescarta), tisagenlecleucel (TIS; Kymriah), and lisocabtagene maraleucel (LIS; Breyanzi), for the treatment of blood cancers. This study concluded that AXI and TIS showed very good...
Read More
In a nutshell This study evaluated the safety and effectiveness of lenalidomide (Revlimid) plus rituximab (Rituxan) for patients with diffuse large B-cell lymphoma (DLBCL) that came back or stopped responding to treatment. This study concluded that this treatment showed some effectiveness, but adding other agents may improve outcomes for these...
Read More
In a nutshell This study aimed to evaluate the efficacy and safety of R-GemOx (rituximab, gemcitabine, and oxaliplatin) for the treatment of patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The authors concluded that R-GemOx is an effective treatment regimen in patients ineligible for intensive treatment. Some...
Read More
In a nutshell This study tested the safety and effectiveness of pirtobrutinib (LOXO-305) in the treatment of patients with B cell leukemia/lymphoma. The authors found that pirtobrutinib was safe and had promising effectiveness in these patients. Some background B cells are a type of cell of the immune system. Some lymphomas and leukemias such as...
Read More
In a nutshell This study aimed to evaluate the safety and effectiveness of loncastuximab tesirine (LoT; Lonca) for the treatment of patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). The study found that LoT was safe and had promising activity in these patients. Some background B-NHL is a type of...
Read More
In a nutshell This study aimed to investigate the combination of bendamustine (Treanda), ofatumumab (Arzerra), carboplatin (Paraplatin), and etoposide (Etopophos) in patients with relapsed/refractory aggressive non-Hodgkin lymphoma (NHL). This study concluded that this combination was safe and effective in these...
Read More
In a nutshell This study aimed to investigate the outcomes of a second hematopoietic stem cell transplant (HSCT) after reduced-intensity conditioning (RIC) for patients with leukemia or lymphoma. This study concluded that this treatment path is feasible and a good treatment alternative for these patients. Some background Allogenic...
Read More
In a nutshell This study will evaluate a three-drug regimen for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL). The primary outcomes are how many patients respond to treatment or have a complete response (cancer no longer detectable). The study will take place in the United States. The details B-cell...
Read More
In a nutshell This study will evaluate the antibody therapy odronextamab for patients with relapsed B-cell non-Hodgkin lymphoma (NHL). The primary outcomes will be how many patients respond to treatment, and how many have a complete response (cancer no longer detectable). The details For B-cell NHL which has relapsed (returned) after...
Read More
In a nutshell This review provided updates to the NCCN guidelines for pediatric aggressive mature B-Cell lymphomas. Some background Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma (NHL) in children. They include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are...
Read More
